Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
The efficacy of immune checkpoint inhibitors varies in clear-cell renal cell carcinoma (ccRCC), with notable primary resistance among patients. Here, we integrate epigenetic (DNA methylation) and transcriptome data to identify a ccRCC subtype characterized by cancer-specific promoter hypermethylation and epigenetic silencing of Polycomb targets. We develop and validate an index of methylation-based epigenetic silencing (iMES) that predicts primary resistance to immune checkpoint inhibition (ICI) in the BIONIKK trial. High iMES is associated with VEGF pathway silencing, endothelial cell depletion, immune activation/suppression, EZH2 activation, BAP1/SETD2 deficiency, and resistance to ICI. Combination therapy with hypomethylating agents or tyrosine kinase inhibitors may benefit patients with high iMES. Intriguingly, tumors with low iMES exhibit increased endothelial cells and improved ICI response, suggesting the importance of angiogenesis in ICI treatment. We also develop a transcriptome-based analogous system for extended applicability of iMES. Our study underscores the interplay between epigenetic alterations and tumor microenvironment in determining immunotherapy response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 4(2023), 11 vom: 21. Nov., Seite 101287 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Xiaofan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 12.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2023.101287 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364591404 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364591404 | ||
| 003 | DE-627 | ||
| 005 | 20240213232607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2023.101287 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1290.xml |
| 035 | |a (DE-627)NLM364591404 | ||
| 035 | |a (NLM)37967556 | ||
| 035 | |a (PII)S2666-3791(23)00481-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Xiaofan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The efficacy of immune checkpoint inhibitors varies in clear-cell renal cell carcinoma (ccRCC), with notable primary resistance among patients. Here, we integrate epigenetic (DNA methylation) and transcriptome data to identify a ccRCC subtype characterized by cancer-specific promoter hypermethylation and epigenetic silencing of Polycomb targets. We develop and validate an index of methylation-based epigenetic silencing (iMES) that predicts primary resistance to immune checkpoint inhibition (ICI) in the BIONIKK trial. High iMES is associated with VEGF pathway silencing, endothelial cell depletion, immune activation/suppression, EZH2 activation, BAP1/SETD2 deficiency, and resistance to ICI. Combination therapy with hypomethylating agents or tyrosine kinase inhibitors may benefit patients with high iMES. Intriguingly, tumors with low iMES exhibit increased endothelial cells and improved ICI response, suggesting the importance of angiogenesis in ICI treatment. We also develop a transcriptome-based analogous system for extended applicability of iMES. Our study underscores the interplay between epigenetic alterations and tumor microenvironment in determining immunotherapy response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a angiogenesis | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a clear-cell renal cell carcinoma | |
| 650 | 4 | |a epigenetic silencing | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Vano, Yann-Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Helleux, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lindner, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Mouawad, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Spano, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Rouprêt, Morgan |e verfasserin |4 aut | |
| 700 | 1 | |a Compérat, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Verkarre, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Cheng-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Bennamoun, Mostefa |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Barthelemy, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Wenxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, Irwin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Fangrong |e verfasserin |4 aut | |
| 700 | 1 | |a Fridman, Wolf Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Sautes-Fridman, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Oudard, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Malouf, Gabriel G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 4(2023), 11 vom: 21. Nov., Seite 101287 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:11 |g day:21 |g month:11 |g pages:101287 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2023.101287 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 11 |b 21 |c 11 |h 101287 | ||